CYC 065

Drug Profile

CYC 065

Alternative Names: CYC-065

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Antineoplastics; Purines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell cycle protein inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Neuroblastoma

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 18 Apr 2016 Pharmacodynamics data from a preclinical trial in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) ,
  • 14 Dec 2015 Interim pharmacodynamics data from a preclinical studies in Cancer presented at the 38th Annual San Antonio Breast Cancer Symposium (SABCS-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top